Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC. Zhou C, et al. Among authors: jayson gc. Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28. Br J Cancer. 2016. PMID: 27351218 Free PMC article. Clinical Trial.
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.
Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. Backen A, et al. Among authors: jayson gc. Clin Cancer Res. 2014 Sep 1;20(17):4549-4558. doi: 10.1158/1078-0432.CCR-13-3248. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947924 Free PMC article. Clinical Trial.
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.
Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C. Jayson GC, et al. Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1. Nat Commun. 2018. PMID: 30405103 Free PMC article. Clinical Trial.
Antiangiogenic therapy for ovarian cancer.
Rosa DD, Clamp AR, Collinson F, Jayson GC. Rosa DD, et al. Among authors: jayson gc. Curr Opin Oncol. 2007 Sep;19(5):497-505. doi: 10.1097/CCO.0b013e32827035f0. Curr Opin Oncol. 2007. PMID: 17762578 Review.
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE. Collinson F, et al. Among authors: jayson gc. Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9. Clin Cancer Res. 2013. PMID: 23935036 Free PMC article. Clinical Trial.
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial. Horsley L, et al. Among authors: jayson gc. Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2013. PMID: 24141375 Clinical Trial.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Among authors: jayson gc. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. Morgan RD, et al. Among authors: jayson gc. Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20. Cancer Chemother Pharmacol. 2018. PMID: 29464354 Free PMC article. Review.
204 results